Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on August 2, 2017. The filing reports a specific corporate event under Item 8.01 (Other Events) regarding a new research grant.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is the value of a new grant award.
- Grant Award: Up to $997,068 over two years.
- Grant Source: National Institutes of Health (NIH) Phase 2 Small Business Innovation Research (SBIR) grant.
Material Changes
The material change reported is the receipt of the NIH grant to fund preclinical research. This represents a new source of non-dilutive funding for the company's pipeline.
Outlook, Management Commentary, and Risks
Management Commentary: The Company announced the grant is intended to evaluate the potential of NSI-189, a novel small molecule compound, for the prevention and treatment of diabetic neuropathy.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties of preclinical research. The grant is contingent upon the conduct of the specified research over the two-year period.
Investor Verification Checklist
- Verify the status of the NSI-189 clinical development program for diabetic neuropathy.
- Confirm the specific milestones required to draw down the full $997,068 grant amount.
- Review the attached Press Release (Exhibit 99.01) for detailed research objectives.
- Note that this filing contains no updated financial position data; refer to the most recent 10-Q or 10-K for liquidity and debt status.